About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global Expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information ESG Contact us
Products Services
Product center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Career
Talent R&D Team Employee Life Job Opportunities
EN
CN
About Us
· Company Introduction · Strategic Development · Social Responsibility
Scientific Research
· Innovative Layout · Innovative Field
Products Services
· Product center · Product branding · Quality & Safety
News
· Company News · Media Coverage · Media Inquiries · Multimedia zone
Vocational
· Concept about Talent · R&D Team · Employee Life · Job Opportunities
> News > Company
Return
Grand Pharma Presents at the 2024 Annual National Rhinology Conference
2024-09-04

Recently, the 2024 National Rhinology Annual Conference and the 15th Symposium on Nasal Infections and Allergic Diseases, which was organized by the Chinese Medical Journal and co-sponsored by the Chinese Journal of Otolaryngology, Head and Neck Surgery of the Chinese Medical Association, the Chinese Branch of Otolaryngology and the World Journal of Otolaryngology, Head and Neck Surgery, was held in Changchun City, Jilin Province, China.

During the exhibition, Grand Pharma brought several of its subsidiaries to the booth, mainly displaying rhinology products. Grand Pharma’s rhinology products are used in outpatient and perioperative rhinology treatment and daily care to protect nasal health.

Prev

Next

Related news

  • <em>The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment</em>
    The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment

    2025-10-26

  • The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment
    The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment

    2025-10-09

  • Grand Pharma’s Treprostinil Injection Has Been Granted a Drug Registration Certificate by NMPA
    Grand Pharma’s Treprostinil Injection Has Been Granted a Drug Registration Certificate by NMPA

    2025-09-24

Grand Pharma Group
About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information Contact us
Products Services
Product Center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Vocational
Concept about Talent R&D Team Employee Life Job Opportunities
Copyright © Grand Pharma (China) Co., Ltd. All Rights Reserved E ICP B 10008288 EGWAB 42010402000597
Legal Provisions